Eagle Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $78.1M | Sell |
|
|||||
|
2024
Q2 | $95.3M | Sell |
|
|||||
|
2024
Q1 | $101M | Sell |
|
|||||
|
2023
Q4 | $96M | Buy |
|
|||||
|
2023
Q3 | $81.8M | Buy |
|
|||||
|
2023
Q2 | $68.5M | Buy |
|
|||||
|
2023
Q1 | $28.2M | Sell |
|
|||||
|
2022
Q4 | $33.4M | Buy |
|
|||||
|
2016
Q4 | – | Sell |
|
|||||
|
2016
Q3 | $46.3M | Sell |
|
|||||
|
2016
Q2 | $42.8M | Sell |
|
|||||
|
2016
Q1 | $40.3M | Sell |
|
|||||
|
2015
Q4 | $62.4M | Sell |
|
|||||
|
2015
Q3 | $44.3M | Sell |
|
|||||
|
2015
Q2 | $63.3M | Buy |
|
|||||
|
2015
Q1 | $51.6M | Buy |
|